EANS-Adhoc: Marinomed Biotech AG announces top line results of the Phase III study for Budesolv
-------------------------------------------------------------------------------- Disclosed inside information pursuant to article 17 Market Abuse Regulation (MAR) transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is responsible for the content of this announcement. -------------------------------------------------------------------------------- Research & Development 23.04.2019 Vienna - Marinomed Biotech AG, a globally active biopharmaceutical company with headquarters in Vienna, has announced the successful completion of the pivotal Phase III study for Budesolv. The top line results are now available and show that Budesolv achieves at least the same effect as the product which is currently on the market, with a significantly lower dose. The planned primary endpoint of the study for the first product of the innovative Marinosolv® technology platform has thus been achieved. The approval process can be continued as scheduled. As announced, the complete Phase III study with detailed results is expected and will be published by the end of the second quarter of 2019 at the latest. Marinosolv® and the flagship product Budesolv Marinomed has succeeded in increasing the bioavailability of hardly soluble compounds to treat sensitive tissues such as nose and eyes via the Marinosolv® technology platform. The platform's flagship product is Budesolv, a nasal spray for the treatment of allergic rhinitis. About Marinomed Biotech AG Marinomed Biotech AG is a biopharmaceutical company with headquarters in Vienna and has been listed in the Prime Market of the Vienna Stock Exchange since February 1, 2019. The company focuses on the development of innovative products based on patent-protected technology platforms in the field of respiratory and ophthalmological diseases. The Marinosolv® technology platform increases the efficacy of hardly soluble compounds for the treatment of sensitive tissues such as the eyes and nose. The Carragelose® platform comprises innovative patent- protected products targeting viral infections of the respiratory tract. Carragelose® is used in nasal sprays, throat sprays and lozenges, which are sold via international partners in over 30 countries worldwide. Further information is available at: www.marinomed.com [http://www.marinomed.com/]. Further inquiry note: Dr. Eva Prieschl-Grassauer Chief Scientific Officer, Marinomed Veterinärplatz 1, 1210 Wien, Austria T +43 (0)1 250 77 446 E-mail: eva.prieschl@marinomed.com http://www.marinomed.com Roland Mayrl Managing Partner, Metrum Communications Prinz-Eugen-Straße 80/16, 1040 Wien, Austria T +43 (0) 1 504 69 87 331 E-mail: r.mayrl@metrum.at http://www.metrum.at end of announcement euro adhoc -------------------------------------------------------------------------------- issuer: Marinomed Biotech AG Veterinärplatz 1 A-1210 Wien phone: 0043250774460 FAX: 0043250774493 mail: office@marinomed.com WWW: www.marinomed.com ISIN: ATMARINOMED6, AT0000A1WD52 indexes: stockmarkets: Wien language: English
Original content of: Marinomed Biotech AG, transmitted by news aktuell